This report aims to explore the events and trends of the biopharmaceutical industry in Q3 (July, August, September). Besides PiaSky, Vyloy, Imdelltra, Tribuvia, and ivonescimab, five more novel antibody drugs have been approved this year:
Enlonstobart (Enshuxing)
Donanemab (Kisunla)
Odronextamab (Ordspono)
Axatilimab (Niktimvo)
Stapokibart (Kangyueda)
This quarter saw an increase in research trends in higher drug–antibody ratios for antibody-drug conjugates (ADCs), with promising approaches to address the problem of high hydrophobicity. Positive results in various clinical trials for anti-TIGIT therapies have also excited the field, with safety and pharmacovigilance at the center after numerous failures. Here, we give an example of a promising monoclonal antibody in development.
Q3 2024 witnessed major collaborations of up to $3 billion USD in value. While acquisitions slow down, investment in antibodies is continuing, with startups raising Series A and Seed rounds of up to $370M USD, primarily focused on multispecifics and bispecifics. We highlight three exciting startups in immunological and inflammatory (I&I) disorders.
There are several exciting antibodies to watch in Q4 which are either in regulatory review or in late-stage clinical trials. These antibodies range from those treating rare genetic disorders to various cancers.
Register now for a free download of the report!
